89
Participants
Start Date
September 20, 2022
Primary Completion Date
September 20, 2027
Study Completion Date
September 20, 2029
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Philadelphia
OTHER
Stephan Grupp MD PhD
OTHER